Esperion Therapeutics, Inc.
ESPR
$0.8709
-$0.1046-10.72%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 27.79% | 52.32% | -201.48% | 208.30% | -36.59% |
| Total Depreciation and Amortization | 3.85% | 160.00% | -- | -- | -76.92% |
| Total Amortization of Deferred Charges | -61.52% | 1.13% | 1.14% | 1.39% | 0.94% |
| Total Other Non-Cash Items | 21.62% | -89.63% | 318.20% | -4.86% | 0.02% |
| Change in Net Operating Assets | -71.56% | -148.45% | 77.07% | -651.28% | -39.88% |
| Cash from Operations | 1.06% | -390.28% | -113.39% | 245.26% | -91.75% |
| Capital Expenditure | 100.00% | -116.88% | -5.48% | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 100.00% | -116.88% | -5.48% | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -94.15% | -90.59% | 965.85% | -- |
| Repurchase of Common Stock | -- | 100.00% | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 1,610.54% | -103.16% | 5,323.87% | -27.42% | -6.64% |
| Cash from Financing | 484.78% | 69.71% | -133.14% | 1,926.53% | 203.69% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 100.10% | -19.52% | -125.84% | 543.03% | -37.86% |